Clinical trial · no report yet · Phase 2
NCT06478043
A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC
- NCT06478043 ↗
- Completed
- Zhejiang Cancer Hospital
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Small-cell Lung Cancer
- Interventions
- ivonescimab; irinotecan liposome
- Arms
- ivonescimab and irinotecan liposome · Experimental
- Enrollment
- 60
- Primary outcomes
- 6-month PFS (progression free survival) rate
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 16, 2024
- Primary completion
- Jun 30, 2026
- Results posted
- No
- Registry record
- NCT06478043 · updated Aug 27, 2026